Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Covington
Moodys
Cipla
McKinsey
Federal Trade Commission
Cerilliant
Mallinckrodt
Johnson and Johnson

Generated: October 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,440,170

« Back to Dashboard

Which drugs does patent 8,440,170 protect, and when does it expire?

Patent 8,440,170 protects SUPRENZA and is included in one NDA.

This patent has three patent family members in two countries.

Summary for Patent: 8,440,170
Title:Orally disintegrating tablets with speckled appearance
Abstract: Orally disintegrating tablets containing colored granules of a water-soluble sugar which give them a speckled appearance are described. The orally disintegrating tablets with speckled appearance are readily and easy identifiable by physicians, nurses and patients.
Inventor(s): Stroppolo; Federico (Mezzovico, CH), Ardalan; Shahbaz (Mezzovico, CH)
Assignee: Alpex Pharma SA (Mezzovico, CH)
Application Number:12/811,737
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,440,170
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form;

Drugs Protected by US Patent 8,440,170

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-001 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-002 Jun 13, 2011 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Citius Pharms SUPRENZA phentermine hydrochloride TABLET, ORALLY DISINTEGRATING;ORAL 202088-003 Mar 27, 2012 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,440,170

PCT Information
PCT FiledJanuary 30, 2009PCT Application Number:PCT/EP2009/051055
PCT Publication Date:August 13, 2009PCT Publication Number: WO2009/098169

International Family Members for US Patent 8,440,170

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2254558 ➤ Sign Up
European Patent Office 2278590 ➤ Sign Up
World Intellectual Property Organization (WIPO) 2009098169 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKesson
US Army
Cerilliant
US Department of Justice
Harvard Business School
Queensland Health
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.